Discovery of Inhibitors for Mycobacterium Tuberculosis Peptide Deformylase Based on Virtual Screening in Silico
- 27 October 2021
- journal article
- research article
- Published by Wiley in Molecular Informatics
- Vol. 41 (3) , 2100002
Abstract
Tuberculosis has been the serious disease threatening human health and public safety due to the emergence of MDR and XDR‐TB. Mycobacterium tuberculosis peptide deformylase (MtPDF) is a valuable target for antituberculotics. In order to discover new potential inhibitor candidates of MtPDF as leads for antituberculotics, Discovery Studio (DS) 2019 was used to perform molecular docking for virtual screening in silico with the bioactive compound library‐I (L1700) against MtPDF. Six compounds with high docking scores and favourable ligand‐protein interactions by LibDock and CDOCKER were selected for the evaluation of the inhibition potencies against MtPDF and Mycobacterium smegmatis. GST‐6×His tagged MtPDF was recombinant expressed and purified firstly by Glutathione Sepharose 4B, and secondly by Ni Sepharose 6 FF after the cleavage of human rhinovirus 3C protease. These compounds showed IC50 values from 0.5 μmol/L to 112 μmol/L against MtPDF, among which CUDC‐101 bearing hydroxamic acid exhibited IC50 of 0.5 μmol/L on MtPDF and MIC against Mycobacterium smegmatis of 32 μg/mL, and Ixazomib Citrate with IC50 of 63 μmol/L and MIC of 16 μg/mL. CUDC‐101 and Ixazomib Citrate are promising as the potential leads for antituberculotics.Keywords
Funding Information
- National Natural Science Foundation of China (31570862)
This publication has 34 references indexed in Scilit:
- Glycine in the conserved motif III modulates the thermostability and oxidative stress resistance of peptide deformylase in Mycobacterium tuberculosisFEMS Microbiology Letters, 2011
- Purification of Proteins Fused to Glutathione S-Transferase2010
- In silico approaches to predicting cancer potency for risk assessment of genotoxic impurities in drug substancesRegulatory Toxicology and Pharmacology, 2010
- CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer ActivityCancer Research, 2010
- Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of CancerJournal of Medicinal Chemistry, 2010
- Peptide Deformylase Inhibitors as Potent Antimycobacterial AgentsAntimicrobial Agents and Chemotherapy, 2006
- An improved crystal form of Plasmodium falciparum peptide deformylaseProtein Science, 2004
- Detailed analysis of grid‐based molecular docking: A case study of CDOCKER—A CHARMm‐based MD docking algorithmJournal of Computational Chemistry, 2003
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976
- On the release of the formyl group from nascent proteinJournal of Molecular Biology, 1968